Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Clin Cancer Res. 2010 Apr 13;16(9):2580–2590. doi: 10.1158/1078-0432.CCR-09-2937

Figure 5. Sulforaphane eradicated breast cancer stem cells in vivo asassessed by re-implantation in secondary mice.

Figure 5

Each secondary NOD/SCID mouse received 50,000 cells from control tumorsin one side of mammary fat pad and another 50,000 cells from sulforaphane-treated tumorsin the contralateral fat pad. (A) Tumor growth curves of the recipient NOD/SCID mice. Data for group 1 are presented as mean ± SD(n = 4), and for group 2 are presented as mean ± SD(n = 3). Sulforaphane abrogated the tumorigenicity of breast cancer stem cells. (B) Percentage of tumor-free mice by the day of euthanization for each group. Four mice were euthanized at day 20 and three at day 33 due to the mass tumor burden on control side.